Clinical trials: sponsored by Canadian Cancer Trials Group
Urothelial Cancer
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
The purpose of this study is to compare the effects on urothelial cancer of nab-paclitaxel compared to paclitaxel to treat this disease.
- Trial name
- NCT02033993
- Testing
- Nab-Paclitaxel, Paclitaxel
- Where
- 37 sites in Australia, Canada
- Volunteers
- 199 people
- Sponsor
- Canadian Cancer Trials Group
Cancer
A Phase I Study of CX5461
CX5461 is a new type of drug for many types of cancer, particularly cancers that cannot easily repair damage to their cells. This may help to slow down the growth of cancer or may cause cancer cells to die.
- Trial name
- NCT02719977
- Testing
- CX5461
- Where
- 3 sites in Canada
- Volunteers
- 41 people
- Sponsor
- Canadian Cancer Trials Group
Recurrent Lymphoma, Refractory Lymphoma
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.
- Conditions
- Recurrent Lymphoma, Refractory Lymphoma, Solid Tumours, Central Nervous System
- Trial name
- NCT02343718
- Testing
- Vinblastine, Temsirolimus
- Where
- 6 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Canadian Cancer Trials Group
Non Small Cell Lung Cancer
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
This research is being done because further research on selumetinib in combination with standard chemotherapy treatment is needed.
- Trial name
- NCT01783197
- Testing
- Paclitaxel, Carboplatin, Selumetinib
- Where
- 4 sites in Canada
- Volunteers
- 39 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Breast Cancer
Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
The purpose of this study is to find the highest dose of durvalumab that can be tolerated without causing very severe side effects when receiving standard treatment and to see what effects the study drug has on this type of…
- Trial name
- NCT02649686
- Testing
- Durvalumab, Trastuzumab
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Colorectal Cancer
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
For the first phase of this study (phase I), the purpose will be to find the dose of a new drug, BKM120, that can safely be given in combination with standard dose panitumumab.
- Trial name
- NCT01591421
- Testing
- BKM120, Panitumumab
- Where
- 3 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Canadian Cancer Trials Group
Glioblastoma Multiforme
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
The standard or usual treatment for this disease is standard chemotherapy alone. AZD2014 is a new type of drug for glioblastoma multiforme. In the laboratory it has been shown to slow the growth of glioblastoma multiforme.
- Trial name
- NCT02619864
- Testing
- AZD2014
- Where
- 4 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out if giving Reolysin in combination with docetaxel and prednisone can offer better results than standard therapy with docetaxel and prednisone.
- Trial name
- NCT01619813
- Testing
- Docetaxel, Reolysin and Prednisone, Docetaxel and Prednisone
- Where
- 11 sites in Canada
- Volunteers
- 85 people
- Sponsor
- Canadian Cancer Trials Group
Gynecologic Cancer
A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects it has on this type of cancer.
- Trial name
- NCT02459301
- Testing
- IPH2201
- Where
- 7 sites in Canada
- Volunteers
- 59 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Breast Cancer
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Researchers doing this study want to evaluate the side effects of Reolysin when given together with paclitaxel. As these drugs have not been given together before, 6-9 patients will be treated with paclitaxel plus reolysin to…
- Trial name
- NCT01656538
- Testing
- Paclitaxel, Reolysin
- Where
- 7 sites in Canada
- Volunteers
- 81 people
- Sponsor
- Canadian Cancer Trials Group
Non Small Cell Lung Cancer
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
The purpose of this study is to find out if giving reolysin in combination with docetaxel or pemetrexed can offer better results than standard therapy with docetaxel or pemetrexed alone.
- Trial name
- NCT01708993
- Testing
- Pemetrexed and Reolysin (and safety run-in), Pemetrexed, Docetaxel and Reolysin
- Where
- 12 sites in Canada
- Volunteers
- 166 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Head and Neck Squamous Cell Carcinoma
PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma
The usual approach for patients who are not in a study is treatment with pembrolizumab, a type of immunotherapy drug. Immunotherapy works by allowing the immune system to detect your cancer and reactivate the immune response.
- Trial name
- PROMOTE-HN (NCT05743777)
- Testing
- Pembrolizumab, MET-4
- Sponsor
- Canadian Cancer Trials Group
Melanoma, Brain Metastases
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown to increase tumour shrinkage in animals…
- Trial name
- NCT02974803
- Testing
- Dabrafenib, Trametinib
- Where
- 6 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Canadian Cancer Trials Group